Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling.

Upreti VV, Wahlstrom JL.

J Clin Pharmacol. 2016 Mar;56(3):266-83. doi: 10.1002/jcph.585. Epub 2015 Oct 9.

PMID:
26139104
2.

Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors.

Foti RS, Pearson JT, Wong SL, Zalikowski JA, Boudreaux MD, Prokop SP, Davis JA, Banfield C, Emery MG, Rock DA, Wahlstrom JL, Wienkers LC, Amore BM.

Drug Metab Dispos. 2012 Dec;40(12):2239-49. doi: 10.1124/dmd.112.047928. Epub 2012 Aug 28.

PMID:
22930276
3.

Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.

Foti RS, Rock DA, Han X, Flowers RA, Wienkers LC, Wahlstrom JL.

J Med Chem. 2012 Feb 9;55(3):1205-14. doi: 10.1021/jm201346g. Epub 2012 Jan 31.

PMID:
22239545
4.

Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition.

VandenBrink BM, Foti RS, Rock DA, Wienkers LC, Wahlstrom JL.

Drug Metab Dispos. 2012 Jan;40(1):47-53. doi: 10.1124/dmd.111.041210. Epub 2011 Oct 5.

PMID:
21976621
5.

Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate.

VandenBrink BM, Foti RS, Rock DA, Wienkers LC, Wahlstrom JL.

Drug Metab Dispos. 2011 Sep;39(9):1546-54. doi: 10.1124/dmd.111.039065. Epub 2011 Jun 22.

PMID:
21697463
6.

Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction.

Foti RS, Rock DA, Pearson JT, Wahlstrom JL, Wienkers LC.

Drug Metab Dispos. 2011 Jul;39(7):1188-95. doi: 10.1124/dmd.111.038505. Epub 2011 Mar 29.

PMID:
21447734
7.

Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation.

Foti RS, Rock DA, Wienkers LC, Wahlstrom JL.

Drug Metab Dispos. 2010 Jun;38(6):981-7. doi: 10.1124/dmd.110.032094. Epub 2010 Mar 4.

PMID:
20203109
8.

Application of cytochrome P450 drug interaction screening in drug discovery.

Foti RS, Wienkers LC, Wahlstrom JL.

Comb Chem High Throughput Screen. 2010 Feb;13(2):145-58. Review.

PMID:
20053168
9.

In vitro inhibition of multiple cytochrome P450 isoforms by xanthone derivatives from mangosteen extract.

Foti RS, Pearson JT, Rock DA, Wahlstrom JL, Wienkers LC.

Drug Metab Dispos. 2009 Sep;37(9):1848-55. doi: 10.1124/dmd.109.028043. Epub 2009 Jun 18.

PMID:
19541824
10.

Prediction of CYP-mediated drug interactions in vivo using in vitro data.

Foti RS, Wahlstrom JL.

IDrugs. 2008 Dec;11(12):900-5. Review.

PMID:
19051152
11.

Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats.

Ghosh S, Chiang PC, Wahlstrom JL, Fujiwara H, Selbo JG, Roberds SL.

Basic Clin Pharmacol Toxicol. 2008 May;102(5):453-8. doi: 10.1111/j.1742-7843.2008.00213.x. Epub 2008 Feb 29.

12.

Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements.

Foti RS, Dickmann LJ, Davis JA, Greene RJ, Hill JJ, Howard ML, Pearson JT, Rock DA, Tay JC, Wahlstrom JL, Slatter JG.

Xenobiotica. 2008 Mar;38(3):264-80. doi: 10.1080/00498250701802514 .

PMID:
18274956
13.

CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles.

Foti RS, Wahlstrom JL.

Drug Metab Dispos. 2008 Mar;36(3):523-8. Epub 2007 Nov 29.

PMID:
18048485
14.

Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates.

Pearson JT, Wahlstrom JL, Dickmann LJ, Kumar S, Halpert JR, Wienkers LC, Foti RS, Rock DA.

Chem Res Toxicol. 2007 Dec;20(12):1778-86. Epub 2007 Nov 15.

PMID:
18001057
15.

Advances in predicting CYP-mediated drug interactions in the drug discovery setting.

Wahlstrom JL, Rock DA, Slatter JG, Wienkers LC.

Expert Opin Drug Discov. 2006 Dec;1(7):677-91. doi: 10.1517/17460441.1.7.677.

PMID:
23495993
16.

The in vitro drug interaction potential of dietary supplements containing multiple herbal components.

Foti RS, Wahlstrom JL, Wienkers LC.

Drug Metab Dispos. 2007 Feb;35(2):185-8. Epub 2006 Nov 8.

PMID:
17093003
17.

CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles.

Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, Tracy TS.

Drug Metab Dispos. 2006 Dec;34(12):1966-75. Epub 2006 Sep 8.

PMID:
16963489
18.

Enzyme source effects on CYP2C9 kinetics and inhibition.

Kumar V, Rock DA, Warren CJ, Tracy TS, Wahlstrom JL.

Drug Metab Dispos. 2006 Nov;34(11):1903-8. Epub 2006 Aug 23.

19.

Mechanism of inactivation of human cytochrome P450 2B6 by phencyclidine.

Jushchyshyn MI, Wahlstrom JL, Hollenberg PF, Wienkers LC.

Drug Metab Dispos. 2006 Sep;34(9):1523-9. Epub 2006 Jun 16.

PMID:
16782764
20.

Influence of fluorescent probe size and cytochrome b5 on drug-drug interactions in CYP2C9.

Hummel MA, Tracy TS, Hutzler JM, Wahlstrom JL, Zhou Y, Rock DA.

J Biomol Screen. 2006 Apr;11(3):303-9. Epub 2006 Feb 20.

PMID:
16490777
21.
22.

A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivatives.

Locuson CW 2nd, Wahlstrom JL, Rock DA, Rock DA, Jones JP.

Drug Metab Dispos. 2003 Jul;31(7):967-71.

PMID:
12814975
23.

Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations.

Hutzler JM, Wienkers LC, Wahlstrom JL, Carlson TJ, Tracy TS.

Arch Biochem Biophys. 2003 Feb 1;410(1):16-24.

PMID:
12559973
24.

Structural model of the regulatory domain of smooth muscle heavy meromyosin.

Wahlstrom JL, Randall MA Jr, Lawson JD, Lyons DE, Siems WF, Crouch GJ, Barr R, Facemyer KC, Cremo CR.

J Biol Chem. 2003 Feb 14;278(7):5123-31. Epub 2002 Nov 21.

25.

Use of kinetic isotope effects to delineate the role of phenylalanine 87 in P450(BM-3).

Rock DA, Boitano AE, Wahlstrom JL, Rock DA, Jones JP.

Bioorg Chem. 2002 Apr;30(2):107-18.

PMID:
12020135
26.

Detritylation of Ethers Using Iodine-Alcohol Reagents: An Acid-Catalyzed Reaction.

Wahlstrom JL, Ronald RC.

J Org Chem. 1998 Aug 21;63(17):6021-6022. No abstract available.

PMID:
11672207
27.

Benign synthesis of 2-ethylhexanoic acid by cytochrome P450cam: enzymatic, crystallographic, and theoretical studies.

French KJ, Strickler MD, Rock DA, Rock DA, Bennett GA, Wahlstrom JL, Goldstein BM, Jones JP.

Biochemistry. 2001 Aug 14;40(32):9532-8.

PMID:
11583152

Supplemental Content

Loading ...
Support Center